Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Q3 2025 value amounting to $158263.0.

  • China SXT Pharmaceuticals' Total Non-Current Liabilities fell 4689.36% to $158263.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $158263.0, marking a year-over-year decrease of 4689.36%. This contributed to the annual value of $211683.0 for FY2025, which is 2816.2% down from last year.
  • China SXT Pharmaceuticals' Total Non-Current Liabilities amounted to $158263.0 in Q3 2025, which was down 4689.36% from $211683.0 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Total Non-Current Liabilities registered a high of $365823.0 during Q1 2023, and its lowest value of $6292.0 during Q1 2021.
  • Over the past 4 years, China SXT Pharmaceuticals' median Total Non-Current Liabilities value was $294667.0 (recorded in 2024), while the average stood at $235178.7.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Total Non-Current Liabilities crashed by 8276.68% in 2021, and later tumbled by 433.4% in 2024.
  • Over the past 4 years, China SXT Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $6292.0 in 2021, then soared by 4850.92% to $311512.0 in 2023, then fell by 4.33% to $298011.0 in 2024, then plummeted by 46.89% to $158263.0 in 2025.
  • Its last three reported values are $158263.0 in Q3 2025, $211683.0 for Q1 2025, and $298011.0 during Q3 2024.